Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients.
COVID-19
Cancer
Hesitancy
SARS-CoV-2
Tolerability
Vaccination
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
25
05
2022
accepted:
29
05
2022
medline:
14
4
2023
pubmed:
23
6
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
Refusal to receive SARS-CoV-2 vaccination poses a threat to fighting the COVID-19 pandemic. Little is known about German cancer patients' attitude towards and experience with SARS-CoV-2 vaccination. Patients were enrolled between 04-11/2021. They completed a baseline questionnaire (BLQ) containing multiple choice questions and Likert items ranging from 1 ("totally disagree") to 11 ("totally agree") regarding their attitude towards vaccination and COVID-19. A follow-up questionnaire (FUQ) was completed after vaccination. 218 patients (43% female) completed BLQ (110 FUQ; 48% female). Most patients agreed to "definitely get vaccinated" (82%) and disagreed with "SARS-CoV-2 vaccination is dispensable due to COVID-19 being no serious threat" (82%; more dissent among men, p = 0.05). Self-assessment as a member of a risk group (p = 0.03) and fear of COVID-19 (p = 0.002) were more common among women. Fear of side effects was more common among women (p = 0.002) and patients with solid or GI tumors (p = 0.03; p < 0.0001). At FUQ, almost all (91%) reported their vaccination to be well tolerated, especially men (p = 0.001). High tolerability correlated with confidence in the vaccine being safe (r = 0.305, p = 0.003). Most patients would agree to get it yearly (78%). After vaccination, patients felt safe meeting friends/family (91%) or shopping (62%). Vacation (32%) or work (22%) were among others considered less safe (less frequent among men, p < 0.05). Acceptance of SARS-CoV-2 vaccination is high and it is well tolerated in this sensitive cohort. However, concerns about vaccine safety remain. Those and gender differences need to be addressed. Our results help identify patients that benefit from pre-vaccination consultation.
Identifiants
pubmed: 35731276
doi: 10.1007/s00432-022-04099-7
pii: 10.1007/s00432-022-04099-7
pmc: PMC9215322
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1985-1992Informations de copyright
© 2022. The Author(s).
Références
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
BMC Public Health. 2021 May 29;21(1):1017
pubmed: 34051770
Cancers (Basel). 2021 Aug 01;13(15):
pubmed: 34359783
Vaccine. 2022 Feb 23;40(9):1191-1197
pubmed: 35125225
Vaccines (Basel). 2021 Jul 12;9(7):
pubmed: 34358193
Ann Oncol. 2021 May;32(5):673-674
pubmed: 33529740
Vaccines (Basel). 2022 Jan 12;10(1):
pubmed: 35062771
Eur J Health Econ. 2020 Sep;21(7):977-982
pubmed: 32591957
Postgrad Med J. 2022 Oct 1;98(1164):756-764
pubmed: 37062994
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401
pubmed: 35277694
Oncol Res Treat. 2022;45(3):112-117
pubmed: 34724665
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Support Care Cancer. 2022 May;30(5):4565-4570
pubmed: 35119521
J Cancer Res Clin Oncol. 2022 Jun;148(6):1363-1374
pubmed: 35218401
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Nat Med. 2022 Mar;28(3):456-459
pubmed: 35273403
Ecohealth. 2021 Mar;18(1):44-60
pubmed: 34086129
PLoS One. 2021 Feb 16;16(2):e0246970
pubmed: 33592035
N Engl J Med. 2022 May 5;386(18):1712-1720
pubmed: 35381126
Vaccines (Basel). 2021 Apr 21;9(5):
pubmed: 33919048
AIDS Behav. 2020 Oct;24(10):2776-2780
pubmed: 32440972
Int Immunopharmacol. 2021 Aug;97:107724
pubmed: 33951558
JAMA Oncol. 2022 May 1;8(5):e220446
pubmed: 35271706
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
JAMA Oncol. 2022 May 1;8(5):748-754
pubmed: 35266953
Nat Commun. 2021 Jul 6;12(1):4015
pubmed: 34230477
Eur J Clin Invest. 2020 Dec;50(12):e13423
pubmed: 33026101
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
Lancet Reg Health Eur. 2022 Jan;12:100253
pubmed: 34729549
BMJ Open. 2021 Jun 15;11(6):e048172
pubmed: 34130963
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2
pubmed: 34133951
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508